Supporting people in hospitals across South Australia through vital health and medical research and improved patient care.
Meet our passionate and dedicated team.
Meet our Board and Governance team.
THRF adopts extremely high transparency standards when reporting our financials.
Supports research into the detection, management & treatment of breast cancer.
Funding research into prostate cancer prevention, detection & treatment.
Improving heart health through advances in knowledge & research to beat heart disease.
Our aim is to reduce & eliminate the high incidence of chronic kidney disease and diabetes.
Supports health and wellbeing research & programs for veterans, emergency service personnel and their families.
Driving collaboration, innovation & research to develop best-practice arts, design & health programs.
Supporting world-class stroke research to improve prevention, diagnosis & acute treatment to cure stroke.
Providing donor stool to treat patients with bowel conditions and foster research into faecal transplant as a treatment.
Do you want to join our team? Check out current career opportunities here.
View some of the commonly asked questions about our organisation.
We are so grateful to those who donate their time and skills to support life-changing medical research. Find out more…
Get in touch with us here.
Researchers at the Lyell McEwin Hospital who are looking at optimal iron treatments for pregnant women have reached a significant milestone in their trial with all 300 patients finishing their appointments.
Iron deficiency is a very common condition amongst pregnant women and can be associated with many risks and potential complications if left untreated.
This study, which began in 2015 and saw biomarkers collected from the 300 participants at four stages of their pregnancy (including delivery), aims to make recommendations around future iron treatments in pregnant women and ensure the safety and long-term outcome of both mum and baby.
“Iron deficiency during pregnancy is critical to diagnose and treat because it can lead to poor outcomes for the mother and can also be detrimental to her child’s development,” said study coordinator Dr Natalie Aboustate.
“Intravenous (IV) iron is an effective treatment option for iron deficiency and we are seeking to determine the dose of IV iron necessary to sustain optimal ferritin levels (the amount of iron in the blood) during the short to long-term perinatal period.”
“Our ultimate aim is to optimise future iron treatments in pregnant women and ensure maternal and foetal safety and long-term outcomes.”
The Hospital Research Foundation is proud to be supporting the next stage of the study, which will include biological analysis of all the biomarkers collected from the patients.
“This analysis is incredibly important because it will allow us to characterise various aspects of iron metabolism during and after pregnancy, much of which is currently unknown.
“All of this research is aimed at improving health and pregnancy outcomes for mothers and their children.”
We look forward to keeping you updated on this exciting research!